Modotuximab (** Currently investigational - no approved brand names available as it remains in clinical development phases. **)

Immunotherapy

EU Experimental ES Not available 1 Clinical Trials

Description

Modotuximab is an experimental immunotherapy drug being studied for colorectal cancer (CRC). It is currently in clinical development and is not yet approved for use. In clinical trials, it has been investigated in combination with other experimental drugs (like SYM004 and futuximab) for patients with metastatic CRC (mCRC). Some trials specifically included patients whose tumors had certain characteristics, such as specific mutations (like EGFR or MET) or MSI-H status. The trials aimed to assess the drug's safety and effectiveness, but enrollment was stopped early. Safety data is still being evaluated.

Mechanism of Action

Modotuximab is designed to target cancer cells. It belongs to the immunotherapy class, which means it aims to help the body's own immune system fight the cancer. The specific way modotuximab interacts with the immune system or cancer cells is being studied in clinical trials.

Side Effects

Because modotuximab is still in clinical development Its full range of side effects is still being evaluated. The clinical trial mentioned (NCT03549338) was terminated early And only safety data is being assessed. Specific side effects observed in trials are not detailed in the provided information But like other immunotherapies Potential side effects could include immune-related adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03549338 Phase 2
Archived
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
United States, Germany, Italy, Spain

Quick Info

Brand Name** Currently investigational - no approved brand names available as it remains in clinical development phases. **
CategoryImmunotherapy
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Bevacizumab
Immunotherapy
512 trials
Cetuximab
Immunotherapy
364 trials
Pembrolizumab
Immunotherapy
196 trials
Panitumumab
Immunotherapy
126 trials
Nivolumab
Immunotherapy
116 trials
Tislelizumab
Immunotherapy
62 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.